Samarth Kulkarni - Dec 3, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol: CRSP
Transactions as of: Dec 3, 2022
Transactions value $: -$1,013,896
Form type: 4
Date filed: 12/6/2022, 04:49 PM
Previous filing: Nov 30, 2022
Next filing: Dec 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+40K	+13.78%		330K	Dec 3, 2022	Direct	F1, F2
transaction	CRSP	Common Shares	Tax liability	-$1.01M	-19.4K	-5.87%	$52.26	311K	Dec 5, 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		+40K			0	Dec 3, 2022	Common Shares	40K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.
F2	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3	On December 3, 2019, the reporting person was granted 120,000 restricted stock units. On December 3, 2022, 40,000 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.